Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Yasuko Iwakiri, PhD

Professor of Medicine (Digestive Diseases)

Contact Information

Yasuko Iwakiri, PhD

Office Location

Mailing Address

  • Yale School of Medicine

    Department of Medicine (Digestive Diseases), PO Box 208019

    New Haven, CT 06520-8019

    United States

Iwakiri Lab
Download CV

Related Links

Research Summary

The central focus of my research is the study of liver fibrosis and portal hypertension. Both are major subjects in the study of liver disease. My laboratory also investigates the role of vascular biology in liver disease pathogenesis. Although the pathology of the liver has examined cellular components and functions of the liver, the contribution of the vasculature both inside and outside the liver and related hemodynamic changes have not been well investigated. This is the uniqueness of my research and originated from my study of portal hypertension, which represents a liver and vascular disease.

Extensive Research Description

Vascular biology of the liver:

My lab has been committed to working on the lymphatic system in the liver, which is a very unexplored area in the study of liver biology (Chung & Iwakiri, CMH, 2013; Iwakiri, Hepatology, 2016; Tanaka & Iwakiri, CMGH, 2016).

Liver fibrosis:

  1. We investigate the role of each major liver cell type in fibrogenesis with a particular interest in hepatic stellate cells (HSC), a cell type that has the most direct impact on the development of fibrosis. We have determined that a protein called Reticulon 4B (a.k.a., Nogo-B) increases fibrosis by promoting collagen production by HSCs (Zhang et al., Hepatology, 2011) and protecting HSCs from apoptosis (Tashiro et al., Am J Pathol, 2013).
  2. In collaboration with Dr. Mark Saltzman (Yale University), we have explored the therapeutic potential of targeting Reticulon 4B in HSCs for liver fibrosis by delivering siRNA encapsulated in nanoparticles. While nanoparticles have been considered an important tool for delivery of drugs and the liver has been known to retain nanoparticles, their cellular distribution in the liver was not clearly understood. We conducted extensive analyses of liver cell uptake of nanoparticles and demonstrated their cellular distribution in vivo for the first time (Park et al., Nanomedicine, 2016). This study is significant since the effectiveness and safety of medical application of nanoparticles for liver therapy depends on their specific delivery to targeted cell populations.

Kupffer cells/macrophages in the pathogenesis of alcohol-induced liver disease:

Alcohol abuse causes liver disease, whose spectrum includes alcoholic fatty liver, alcoholic hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma in a progressive manner. Early intervention may prevent progression to cirrhosis and hepatocellular carcinoma, but effective treatments are limited due to our incomplete understanding of the molecular and cellular mechanisms of alcohol-induced liver injury. My lab studies the mechanism of alcohol-induced liver injury, in which Kupffer cells (liver resident macrophages) have a pivotal role. We also explore therapeutic potential of nanoparticle delivery to Kupffer cells for the treatment of alcoholic liver disease.

Coauthors

Research Interests

Fibrosis; Hypertension, Portal; Kupffer Cells; Liver Regeneration; Pancreatitis; Splenomegaly; Vascular Diseases; Lymphangiogenesis; Endothelial Cells

Public Health Interests

Cancer; Cardiovascular Diseases

Research Image

Immune cell infiltration to the portal tract of the liver

Macrophages (green) and T-cells (red) are infiltrated to the portal tract area of the liver in response to the induction of portal hypertension in rats. These cells play roles for portal tract fibrosis in the liver.

Selected Publications

Edit Profile